Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280607631> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4280607631 endingPage "100339" @default.
- W4280607631 startingPage "100339" @default.
- W4280607631 abstract "Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of concurrent anlotinib and chemoradiotherapy are still unclear.Patients with histologically or cytologically confirmed stage III NSCLC suitable for concurrent chemoradiotherapy were enrolled in this study. The enrolled patients were treated with concurrent two cycles of anlotinib and chemoradiotherapy followed by anlotinib consolidation until disease progression or intolerance toxicity. The primary end point was the maximum tolerance dose of anlotinib, whereas the secondary end point was the overall response rate.Seven patients were enrolled in this study. Six patients completed concurrent anlotinib and chemoradiotherapy and then entered the consolidation period. Among the patients, 28.57% (two of seven patients) developed fatal treatment-related adverse events (fatal pneumonitis and fatal hemoptysis). In addition, two other patients developed grade 3 radiation pneumonitis; one was induced by a cold, and the patient received only 18 Gy per nine fractions of radiotherapy. This study was terminated early owing to the high rate of fatal adverse events and radiation pneumonitis.This study presented severe pulmonary toxicity with concurrent anlotinib and chemoradiotherapy. Several previous clinical trials evaluated the safety of concurrent bevacizumab and radiotherapy or chemoradiotherapy; all were terminated owing to severe treatment-related toxicity. Results of these studies suggest that concurrent antiangiogenic and thoracic radiotherapy should be avoided until appropriate safety data are presented, at least for bevacizumab and anlotinib." @default.
- W4280607631 created "2022-05-22" @default.
- W4280607631 creator A5000616499 @default.
- W4280607631 creator A5014603317 @default.
- W4280607631 creator A5017134771 @default.
- W4280607631 creator A5019707913 @default.
- W4280607631 creator A5048171248 @default.
- W4280607631 creator A5082684637 @default.
- W4280607631 date "2022-06-01" @default.
- W4280607631 modified "2023-09-30" @default.
- W4280607631 title "Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial" @default.
- W4280607631 cites W2103426155 @default.
- W4280607631 cites W2112768035 @default.
- W4280607631 cites W2171835824 @default.
- W4280607631 cites W2806810471 @default.
- W4280607631 cites W2808043936 @default.
- W4280607631 cites W2885503610 @default.
- W4280607631 cites W2889570909 @default.
- W4280607631 cites W2893824814 @default.
- W4280607631 cites W2931087051 @default.
- W4280607631 cites W2965089489 @default.
- W4280607631 cites W2981634585 @default.
- W4280607631 cites W3118248931 @default.
- W4280607631 cites W3126928179 @default.
- W4280607631 cites W3162065781 @default.
- W4280607631 cites W3164336527 @default.
- W4280607631 cites W3196453900 @default.
- W4280607631 doi "https://doi.org/10.1016/j.jtocrr.2022.100339" @default.
- W4280607631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35663415" @default.
- W4280607631 hasPublicationYear "2022" @default.
- W4280607631 type Work @default.
- W4280607631 citedByCount "1" @default.
- W4280607631 countsByYear W42806076312023 @default.
- W4280607631 crossrefType "journal-article" @default.
- W4280607631 hasAuthorship W4280607631A5000616499 @default.
- W4280607631 hasAuthorship W4280607631A5014603317 @default.
- W4280607631 hasAuthorship W4280607631A5017134771 @default.
- W4280607631 hasAuthorship W4280607631A5019707913 @default.
- W4280607631 hasAuthorship W4280607631A5048171248 @default.
- W4280607631 hasAuthorship W4280607631A5082684637 @default.
- W4280607631 hasBestOaLocation W42806076311 @default.
- W4280607631 hasConcept C126322002 @default.
- W4280607631 hasConcept C141071460 @default.
- W4280607631 hasConcept C143998085 @default.
- W4280607631 hasConcept C197934379 @default.
- W4280607631 hasConcept C203092338 @default.
- W4280607631 hasConcept C2776694085 @default.
- W4280607631 hasConcept C2777714996 @default.
- W4280607631 hasConcept C2777802072 @default.
- W4280607631 hasConcept C2778424827 @default.
- W4280607631 hasConcept C2779524853 @default.
- W4280607631 hasConcept C2781047374 @default.
- W4280607631 hasConcept C29730261 @default.
- W4280607631 hasConcept C31760486 @default.
- W4280607631 hasConcept C509974204 @default.
- W4280607631 hasConcept C535046627 @default.
- W4280607631 hasConcept C71924100 @default.
- W4280607631 hasConceptScore W4280607631C126322002 @default.
- W4280607631 hasConceptScore W4280607631C141071460 @default.
- W4280607631 hasConceptScore W4280607631C143998085 @default.
- W4280607631 hasConceptScore W4280607631C197934379 @default.
- W4280607631 hasConceptScore W4280607631C203092338 @default.
- W4280607631 hasConceptScore W4280607631C2776694085 @default.
- W4280607631 hasConceptScore W4280607631C2777714996 @default.
- W4280607631 hasConceptScore W4280607631C2777802072 @default.
- W4280607631 hasConceptScore W4280607631C2778424827 @default.
- W4280607631 hasConceptScore W4280607631C2779524853 @default.
- W4280607631 hasConceptScore W4280607631C2781047374 @default.
- W4280607631 hasConceptScore W4280607631C29730261 @default.
- W4280607631 hasConceptScore W4280607631C31760486 @default.
- W4280607631 hasConceptScore W4280607631C509974204 @default.
- W4280607631 hasConceptScore W4280607631C535046627 @default.
- W4280607631 hasConceptScore W4280607631C71924100 @default.
- W4280607631 hasFunder F4320321001 @default.
- W4280607631 hasIssue "6" @default.
- W4280607631 hasLocation W42806076311 @default.
- W4280607631 hasLocation W42806076312 @default.
- W4280607631 hasLocation W42806076313 @default.
- W4280607631 hasOpenAccess W4280607631 @default.
- W4280607631 hasPrimaryLocation W42806076311 @default.
- W4280607631 hasRelatedWork W1983576003 @default.
- W4280607631 hasRelatedWork W2021910092 @default.
- W4280607631 hasRelatedWork W2110506075 @default.
- W4280607631 hasRelatedWork W2144997803 @default.
- W4280607631 hasRelatedWork W2315260912 @default.
- W4280607631 hasRelatedWork W2794605011 @default.
- W4280607631 hasRelatedWork W2995532498 @default.
- W4280607631 hasRelatedWork W3004966710 @default.
- W4280607631 hasRelatedWork W4280607631 @default.
- W4280607631 hasRelatedWork W4282931604 @default.
- W4280607631 hasVolume "3" @default.
- W4280607631 isParatext "false" @default.
- W4280607631 isRetracted "false" @default.
- W4280607631 workType "article" @default.